QUECTEL-WIRELESS
12.6.2024 11:06:35 CEST | Business Wire | Press release
Introducing the latest innovation in short-range communication technology, Quectel Wireless Solutions, a global IoT solutions provider, today unveils five modules, designed to transform IoT through seamless Wi-Fi and Bluetooth connectivity and offering unparalleled performance, reliability, and versatility, catering to the diverse needs of IoT worldwide.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240612636711/en/
Quectel revolutionizes short-range communication adding five new Wi-Fi and Bluetooth modules to its portfolio (Photo: Business Wire)
“We’re aiming to redefine the landscape of short-range communication technology with this range of five different modules,” commented Norbert Muhrer, President and CSO, Quectel Wireless Solutions. “From lightning-fast Wi-Fi to robust Bluetooth connectivity, our latest innovations promise unparalleled performance, reliability, and versatility. With compact designs tailored to meet the demands of size-sensitive applications, these modules empower IoT solutions worldwide to reach new heights of connectivity and efficiency."
The FCS866R and FCE863R are high performance Wi-Fi 6 and Bluetooth 5.2 modules boasting 2T2R capabilities packaged in an LCC format. Both modules are ideal for WLAN and Bluetooth connections, delivering lightning-fast data rates of up to 1201Mbps. At just 15.0mm × 13.0mm × 2.0mm for the FCS866R and 15.0 mm × 13.0 mm × 2.2 mm for the FCE863R, both modules optimize size and cost for end-products, catering perfectly to size-sensitive applications.
The FCS866R is designed with a reliable SDIO 3.0 interface to provide WLAN capability, the module achieves low-power and high-speed data transmission, while the FCE863R uses the reliable PCIe 1.1 interface to achieve high-speed and low-power WLAN wireless transmission. The FCE863R can support industrial operating temperatures of -40 to around +85°C.
The FGS061N is another Wi-Fi 6 and Bluetooth 5.2 module, this time housed in an LGA package. Operating under the IEEE 802.11ax standard protocol, it supports MCS 0–MCS 11 rates within an 80 MHz bandwidth, with 1024QAM support. Boasting a reliable SDIO 3.0 interface, it ensures seamless WLAN capability.
The FC906A is a robust Wi-Fi 5 and Bluetooth 5.2 module packaged in LCC format. Designed for establishing both WLAN and Bluetooth connections, it operates under IEEE 802.11ac mode, supporting rates from MCS 0–MCS 8 in 20 MHz channels and MCS 0–MCS 9 in 40 MHz and 80 MHz channels. With 256QAM support, it achieves a maximum data rate of up to 433.3 Mbps, while also ensuring compatibility with all rates specified in IEEE 802.11a/b/g/n standards.
Equipped with a reliable SDIO 3.0 interface for WLAN capability, the FC906A includes 2.4 GHz and 5 GHz transmit power amplifiers and low noise amplifiers. On the Bluetooth front, it complies with Bluetooth 5.2 standards, featuring a Class 1 power amplifier for extended range. Plus, it supports Extended Synchronous Connection Oriented link (eSCO) for enhanced voice quality and Adaptive Frequency Hopping (AFH) to minimize radio frequency interference.
Finally, the FCS945R is a dual band Wi-Fi 4 and Bluetooth 5.2 module designed for WLAN and Bluetooth connections. Operating under IEEE 802.11n mode, it achieves a maximum data rate of up to 150 Mbps. With its LCC form factor and ultra-compact package size of just 12.0mm × 12.0mm × 2.15mm, the FCS945R is optimized for size and cost, perfectly meeting the requirements of size-sensitive applications, and can support industrial operating temperatures of -40 to +85°C.
The five modules are available in either LCC or LGA package and the surface-mount technology (SMT), alongside the low profile and small size ensure that all five modules can be easily embedded into size-constrained applications to provide reliable connectivity.
Quectel’s IoT modules are developed with security at the core. From product architecture to firmware/software development, Quectel incorporates leading industry practices and standards, mitigating potential vulnerabilities with third party independent test houses and have incorporated security practices like generating SBOMs and VEX files as well as performing firmware binary analysis into the entire software development lifecycle.
More information on the short-range module range can be found on the Quectel website.
About Quectel
Quectel’s passion for a smarter world drives us to accelerate IoT innovation. A highly customer-centric organization, we are a global IoT solutions provider backed by outstanding support and services. Our growing global team of 5,900 professionals sets the pace for innovation in cellular, GNSS, Wi-Fi and Bluetooth modules as well as antennas and services.
With regional offices and support across the globe, our international leadership is devoted to advancing IoT and helping build a smarter world.
For more information, please visit: www.quectel.com, LinkedIn, Facebook, and X.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240612636711/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release
Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (
Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release
Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,
BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release
The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu
Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release
Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo
Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 08:00:00 CET | Press release
Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets. “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.” Throughout his career, Dan has held senior leadership roles i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
